The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

A holistic or integrative approach to hair loss considers the hair growth cycle and hair loss from a nutritional, ...

The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...

Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug ...

Novartis AG (NYSE:NVS), a global healthcare powerhouse with a market capitalization of $208.27 billion, has recently transformed into a pure-play pharmaceutical company, sharpening its focus on its ...

Novartis on Friday posted quarterly adjusted net income well above analyst estimates on forecast-beating sales of established ...

Novartis AG's ( VTX:NOVN ) dividend will be increasing from last year's payment of the same period to $3.50 on 13th ...

CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if ...

Novartis has become the latest drugmaker to get in trouble over an employee’s LinkedIn likes. The U.K. | Novartis has become ...

Deutsche Bank upgraded Novartis (NVS) to Buy from Hold with a price target of CHF 110, up from CHF 100. The firm says the company’s ...

Additionally, as the Sandoz spin-off was completed on October 2023, there were no operating results in 2024 related to discontinued operations.